Food and Drug AdministrationImportant note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow
Print this Article


Final Guidance: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products

Food and Drug Administration - March 7, 2007
Richard Klein

FDA has issued final guidance, entitled "Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)," to assist establishments making donor eligibility determinations to comply with the requirements for determining donor-eligibility, including donor screening and testing for donors of human cells, tissues, and cellular and tissue-based products. (for background, see http://www.fda.gov/oashi/aids/listserve/listserve2004.html#screen)

The guidance applies to cells and tissues procured on or after the effective date of the regulations contained in 21 CFR part 1271, subpart C (effective date May 25, 2005). It does not replace the guidance concerning 21 CFR part 1270, entitled "Guidance for Industry: Screening and Testing of Donors of Human Tissue Intended for Transplantation ," which remains applicable to tissues recovered before May 25, 2005, and subject to 21 CFR part 1270.

The document provides guidance on donor-eligibility determination, donor screenings, donor testing requirements (including HIV), additional screening and testing requirements for reproductive cells and tissues, and exceptions from the requirements for determining donor-eligibility, and special circumstances.

You can find the complete guidance document on the FDA web site at http://www.fda.gov/cber/gdlns/tissdonor.htm

Richard Klein | HIV/AIDS Program Director | Food and Drug Administration


070307
FD070301

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .